{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:06:44Z","timestamp":1788314804350,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12265-025-10667-2","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:20:50Z","timestamp":1753280450000},"page":"1432-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancement of the Mayo Clinic HCM Genotype Predictor Score with Addition of Cardiac Magnetic Resonance Imaging"],"prefix":"10.1007","volume":"18","author":[{"given":"Iuri","family":"Ferreira Felix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Karlinski Vizentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Alzate-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrie","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Araoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Giudicessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R.","family":"Ommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide M.","family":"Arruda-Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-2003","authenticated-orcid":false,"given":"J. Martijn","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"10667_CR1","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","volume":"287","author":"BJ Maron","year":"2002","unstructured":"Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308\u201320. https:\/\/doi.org\/10.1001\/jama.287.10.1308.","journal-title":"JAMA"},{"key":"10667_CR2","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.108.804617","volume":"119","author":"BJ Maron","year":"2009","unstructured":"Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980\u20132006. Circulation. 2009;119:1085\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.804617.","journal-title":"Circulation"},{"key":"10667_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/s0735-1097(86)80283-2","volume":"7","author":"BJ Maron","year":"1986","unstructured":"Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986;7:204\u201314. https:\/\/doi.org\/10.1016\/s0735-1097(86)80283-2.","journal-title":"J Am Coll Cardiol"},{"key":"10667_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/CIRCGENETICS.112.962928","volume":"5","author":"JR Golbus","year":"2012","unstructured":"Golbus JR, Puckelwartz MJ, Fahrenbach JP, et al. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet. 2012;5:391\u20139. https:\/\/doi.org\/10.1161\/CIRCGENETICS.112.962928.","journal-title":"Circ Cardiovasc Genet"},{"key":"10667_CR5","doi-asserted-by":"publisher","first-page":"e002460","DOI":"10.1161\/CIRCGEN.119.002460","volume":"12","author":"J Ingles","year":"2019","unstructured":"Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genomic Precis Med. 2019;12:e002460. https:\/\/doi.org\/10.1161\/CIRCGEN.119.002460.","journal-title":"Circ Genomic Precis Med"},{"key":"10667_CR6","doi-asserted-by":"publisher","unstructured":"Hespe S, Waddell A, Asatryan B, et al. ClinGen hereditary cardiovascular disease gene curation expert panel: reappraisal of genes associated with hypertrophic cardiomyopathy; 2024. Available from: medRxiv https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2024.07.29.24311195v1","DOI":"10.1101\/2024.07.29.24311195v1"},{"key":"10667_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2024. https:\/\/doi.org\/10.1161\/CIR.0000000000001250.","journal-title":"Circulation"},{"key":"10667_CR8","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75:2649\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064.","journal-title":"J Am Coll Cardiol"},{"key":"10667_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2020;396:759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet Lond Engl"},{"key":"10667_CR10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8:968\u201377. https:\/\/doi.org\/10.1001\/jamacardio.2023.3342.","journal-title":"JAMA Cardiol"},{"key":"10667_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.mayocp.2023.11.019","volume":"99","author":"JR Giudicessi","year":"2024","unstructured":"Giudicessi JR, Alsidawi S, Geske JB, et al. Genotype influences mavacamten responsiveness in obstructive hypertrophic cardiomyopathy. Mayo Clin Proc. 2024;99:341\u20133. https:\/\/doi.org\/10.1016\/j.mayocp.2023.11.019.","journal-title":"Mayo Clin Proc"},{"key":"10667_CR12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/gim.2013.44","volume":"15","author":"J Ingles","year":"2013","unstructured":"Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med Off J Am Coll Med Genet. 2013;15:972\u20137. https:\/\/doi.org\/10.1038\/gim.2013.44.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10667_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/gim.2014.205","volume":"17","author":"AA Alfares","year":"2015","unstructured":"Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med Off J Am Coll Med Genet. 2015;17:880\u20138. https:\/\/doi.org\/10.1038\/gim.2014.205.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10667_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jacc.2018.04.078","volume":"72","author":"RD Bagnall","year":"2018","unstructured":"Bagnall RD, Ingles J, Dinger ME, et al. Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;72:419\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.078.","journal-title":"J Am Coll Cardiol"},{"key":"10667_CR15","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138:1387\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033200.","journal-title":"Circulation"},{"key":"10667_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1161\/CIRCGENETICS.112.963363","volume":"6","author":"C Gruner","year":"2013","unstructured":"Gruner C, Ivanov J, Care M, et al. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013;6:19\u201326. https:\/\/doi.org\/10.1161\/CIRCGENETICS.112.963363.","journal-title":"Circ Cardiovasc Genet"},{"key":"10667_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.mayocp.2014.01.025","volume":"89","author":"JM Bos","year":"2014","unstructured":"Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89:727\u201337. https:\/\/doi.org\/10.1016\/j.mayocp.2014.01.025.","journal-title":"Mayo Clin Proc"},{"key":"10667_CR18","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European society of cardiology (ESC). Eur Heart J. 2023;44:3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"},{"key":"10667_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12265-016-9681-5","volume":"9","author":"SL Murphy","year":"2016","unstructured":"Murphy SL, Anderson JH, Kapplinger JD, et al. Evaluation of the mayo clinic phenotype-based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2016;9:153\u201361. https:\/\/doi.org\/10.1007\/s12265-016-9681-5.","journal-title":"J Cardiovasc Transl Res"},{"key":"10667_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1253\/circj.CJ-20-0826","volume":"85","author":"T Moriki","year":"2021","unstructured":"Moriki T, Kubo T, Sugiura K, et al. A validation study of the mayo clinic phenotype-based genetic test prediction score for Japanese patients with hypertrophic cardiomyopathy. Circ J. 2021;85:669\u201374. https:\/\/doi.org\/10.1253\/circj.CJ-20-0826.","journal-title":"Circ J"},{"key":"10667_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5114\/aoms.2018.78767","volume":"15","author":"J Bonaventura","year":"2019","unstructured":"Bonaventura J, Norambuena P, Toma\u0161ov P, et al. The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy. Arch Med Sci AMS. 2019;15:641\u20139. https:\/\/doi.org\/10.5114\/aoms.2018.78767.","journal-title":"Arch Med Sci AMS"},{"key":"10667_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","volume":"100","author":"TF Ismail","year":"2014","unstructured":"Ismail TF, Jabbour A, Gulati A, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart Br Card Soc. 2014;100:1851\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2013-305471.","journal-title":"Heart Br Card Soc"},{"key":"10667_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med Off J Am Coll Med Genet. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10667_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12968-019-0561-4","volume":"21","author":"P Freitas","year":"2019","unstructured":"Freitas P, Ferreira AM, Arteaga-Fern\u00e1ndez E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson. 2019;21:50. https:\/\/doi.org\/10.1186\/s12968-019-0561-4.","journal-title":"J Cardiovasc Magn Reson"},{"key":"10667_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1148\/radiol.10090526","volume":"258","author":"CJ Harrigan","year":"2011","unstructured":"Harrigan CJ, Peters DC, Gibson CM, et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011;258:128\u201333. https:\/\/doi.org\/10.1148\/radiol.10090526.","journal-title":"Radiology"},{"key":"10667_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-i","volume":"62","author":"AA Geisterfer-Lowrance","year":"1990","unstructured":"Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999\u20131006. https:\/\/doi.org\/10.1016\/0092-8674(90)90274-i.","journal-title":"Cell"},{"key":"10667_CR27","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJM198911163212005","volume":"321","author":"JA Jarcho","year":"1989","unstructured":"Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989;321:1372\u20138. https:\/\/doi.org\/10.1056\/NEJM198911163212005.","journal-title":"N Engl J Med"},{"key":"10667_CR28","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/eurheartj\/ehx819","volume":"39","author":"P Charron","year":"2018","unstructured":"Charron P, Elliott PM, Gimeno JR, et al. The cardiomyopathy registry of the EURObservational research programme of the European society of cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;39:1784\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehx819.","journal-title":"Eur Heart J"},{"key":"10667_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/jgc4.1604","volume":"31","author":"AL Cirino","year":"2022","unstructured":"Cirino AL, Harris SL, Murad AM, et al. The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy\u2014A systematic review and meta-analysis. J Genet Couns. 2022;31:1290\u2013305. https:\/\/doi.org\/10.1002\/jgc4.1604.","journal-title":"J Genet Couns"},{"key":"10667_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.hrthm.2019.06.015","volume":"17","author":"LM Knight","year":"2020","unstructured":"Knight LM, Miller E, Kovach J, et al. Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy. Heart Rhythm. 2020;17:106\u201312. https:\/\/doi.org\/10.1016\/j.hrthm.2019.06.015.","journal-title":"Heart Rhythm"},{"key":"10667_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pcad.2020.11.001","volume":"66","author":"NJ Kamp","year":"2021","unstructured":"Kamp NJ, Chery G, Kosinski AS, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Prog Cardiovasc Dis. 2021;66:10\u20136. https:\/\/doi.org\/10.1016\/j.pcad.2020.11.001.","journal-title":"Prog Cardiovasc Dis"},{"issue":"23","key":"10667_CR32","doi-asserted-by":"publisher","first-page":"00346","DOI":"10.1016\/j.jcmg.2023.07.005","volume":"S1936\u2013878","author":"A Kiaos","year":"2023","unstructured":"Kiaos A, Daskalopoulos GN, Kamperidis V, et al. Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: a meta-analysis. JACC Cardiovasc Imaging. 2023;S1936\u2013878(23):00346\u20137. https:\/\/doi.org\/10.1016\/j.jcmg.2023.07.005.","journal-title":"JACC Cardiovasc Imaging"},{"key":"10667_CR33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4065\/83.6.630","volume":"83","author":"I Olivotto","year":"2008","unstructured":"Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83:630\u20138. https:\/\/doi.org\/10.4065\/83.6.630.","journal-title":"Mayo Clin Proc"},{"key":"10667_CR34","doi-asserted-by":"publisher","first-page":"e0217612","DOI":"10.1371\/journal.pone.0217612","volume":"14","author":"RJH Miller","year":"2019","unstructured":"Miller RJH, Heidary S, Pavlovic A, et al. Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PLoS ONE. 2019;14:e0217612. https:\/\/doi.org\/10.1371\/journal.pone.0217612.","journal-title":"PLoS ONE"},{"key":"10667_CR35","doi-asserted-by":"publisher","first-page":"e005372","DOI":"10.1161\/CIRCIMAGING.116.005372","volume":"10","author":"MS Maron","year":"2017","unstructured":"Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017;10:e005372. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005372.","journal-title":"Circ Cardiovasc Imaging"},{"key":"10667_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","volume":"130","author":"RH Chan","year":"2014","unstructured":"Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484\u201395. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.007094.","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s12265-025-10674-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000}}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10667-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:11:50Z","timestamp":1763565110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10667-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10667"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10667-2","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12265-025-10674-3","URL":"https:\/\/doi.org\/10.1007\/s12265-025-10674-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and followed the Declaration of Helsinki for ethical standards in research with humans. The study was approved by the Mayo Clinic Institutional Review Board (IRB protocol # 17\u2013003392).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Due to its retrospective nature, informed consent was waived by the Mayo Clinic\u2019s Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No animal studies were carried out by the authors for this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal Studies"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"Dr. Ackerman is a consultant for Abbott, BioMarin Pharmaceutical, Boston Scientific, Bristol Myers Squibb, Illumina, Invitae, Medtronic, Tenaya Therapeutics, and UpToDate. Dr. Ackerman and Mayo Clinic are\/were involved in an equity\/intellectual property\/royalty relationship with AliveCor, Anumana, ARMGO Pharma, Prolaio, Solid Biosciences, and Thryv Therapeutics.Dr. Giudicessi is a consultant for Avidity Biosciences and Citizen Health, has Grants\/Clinical Trials sponsored by Tenaya Therapeutics, and has Equity\/Royalty in Prolaio through Mayo Clinic Ventures.Remaining authors have no other disclosures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}